1A
1ARG.LSE LS ARK Genomic Revolution Tracker ETP Securities
- USD
No recent price
- Total assets
- 700K
- Expense ratio
- 1.10%
- Dividend yield
- -
- 1-year return
- -20.76%
- Holdings
- 1
- Since
- 2021
Fund data as reported by the issuer, updated Nov 3, 2026. Total assets are in the fund's base currency.
What does 1ARG.LSE invest in?
Tracks Morningstar Gbl Biotechnology NR USD- Mostly US stocks (92.7%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (93.0%)
- Top 3 holdings: 104.8% of the fund
Asset allocation
- US stocks 92.7%
- Non-US stocks 7.9%
- Cash 0.4%
Top holdings
- ARK Genomic Revolution ETF 104.82%
LS ARK Genomic Revolution Tracker ETP Securities performance
Sharpe ratio 0.71- This year
- -51.58%
- 1 year
- -20.76%
- 3 years
- -19.45%
- 5 years
- 0.00%
Volatility 42.8% over 1 year and 39.4% over 3 years. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
1ARG.LSE price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
LS ARK Genomic Revolution Tracker ETP Securities top holdings
104.8% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| ARK Genomic Revolution ETF ARKG.US | - | United States | 104.82% |
1ARG.LSE sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
1ARG.LSE regional exposure
- North America93.0%
- Europe Developed5.2%
- United Kingdom2.6%
Share of the stocks in the fund.
Company size
Average market cap 7.32B- Mega cap4.0%
- Medium cap19.7%
- Small cap36.0%
- Micro cap29.5%
LS ARK Genomic Revolution Tracker ETP Securities fund profile
- Fund name
- LS ARK Genomic Revolution Tracker ETP Securities
- Ticker
- 1ARG.LSE
- Exchange
- London Exchange
- Issuer
- Leverage Shares PLC
- Index tracked
- Morningstar Gbl Biotechnology NR USD
- Category
- Healthcare Equity
- Domicile
- Ireland
- Inception date
- Dec 10, 2021
- Trading currency
- USD
- Expense ratio
- 1.10%